November 19, 2026
FDA approves Regeneron’s Livsayis for generalised myasthenia gravis
The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals’ Livsayis (cemdisiran) to treat generalised myasthenia gravis (gMG) in adult patients positive for anti-acetylcholine receptor (AChR) antibodies.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







